Fall Clinical News: Tralokinumab Shows Long-Term Safety and Efficacy in AD
LEO Pharma Inc.’s tralokinumab (Adbry) demonstrated safety and efficacy in adults and adolescent patients with moderate-to-severe atopic dermatitis (AD) for up to five years, according to the final results from the ECZTEND extension study. Interim analyses have previously demonstrated the safety and efficacy of the interleukin (IL)-13 blocker in patients followed up to 4.5 years […]